-
Opdivo-Cabometyx program approved by FDA...
Time of Update: 2021-03-09
Opdivo and Cabomyx"immunity plus targeting" combinations have been approved through the Priority Review Program and the Real-Time Oncology Review (RTOR) pilot project for all international metastatic kidney cancer database alliance (IMDC) risk classifications, providing an important, new first-line treatment for the previously untreated group of patients with advanced or metastatic RCC.
-
Treatment of 8 months of huge liver tumor disappeared advanced liver cancer patients "tumor-free survival" into ...
Time of Update: 2021-03-09
After consultation and careful consideration, Professor Li Gong developed a "triple drug program" for PD-1 combined levatininie and lanadamine, and at the same time, once a week to test liver and kidney function, blood routine and a fetal protein, and regularly monitor the physical condition after medication and the progress of the tumor.
-
The IPO tide continues! Ten more pharmaceutical companies have filed for a U.S. stock market listing
Time of Update: 2021-03-09
4Terns Pharmaceuticals CEO: Senthil Sundaram Stock Code: TERN Filing Date: 2021.1.15 Estimated Fundraising: $100 million Company Profile: Terns was founded in 2016 and is headquartered in California, USA, as a Phase II biotechnology company developing small molecule therapies for NASH (non-alcoholic fatty hepatitis).
-
2020 Tumor New Drug Data Card - Zebtinib
Time of Update: 2021-03-09
Brukinsa is NMPA approved for the treatment of R/R CLL/SLL patients and is based on a single-arm, critical Phase 2 clinical trial in China (BGB-3111-205).
-
Baizean, Baiji Shenzhou® phase 3 clinical trial of esophageal squamous cell carcinoma has been positively closed...
Time of Update: 2021-03-09
Today, Baiji Shenzhou announced that its phase 3 global Phase 3 clinical trial to evaluate anti-PD-1 antibody Bazean® compared to the chemotherapy chosen by the researchers for the treatment of advanced non-removable or metastatic esophageal squamous cell carcinoma that has been treated throughout the body in the past has reached the primary endpoint of total survival.
-
And Huang Medicine Su comfort country: based on China synchronization of global high-quality drug innovation steady...
Time of Update: 2021-03-09
, Mr Su said: "Any commercial company needs to be profitable to support subsequent research investment in order to achieve sustainable development." For and Yellow Medicine, whether it's pyridoquine or Sovantini, these original and innovative drugs, which are rooted in China, will always adhere to the concept of maximum patient accessibility and affordability as a commercialization.
-
2020 Tumor New Drug Data Card - Atili Zhu monoanti
Time of Update: 2021-03-09
Advanced non-small cell lung cancer anti-angiogenesic drug therapy China expert consensus (2020 version) recommendation 2: In patients with advanced non-scale NSCLC who drive gene mutation negative and PS 0 to 1 points, recommended atilijutin monoantigen combined beva bead monoanti, carpentry and yew alcohol program as a first-line treatment option (II.grade recommendation, class 1A evidence).
-
2020 Tumor New Drug Data Card - Nairatini
Time of Update: 2021-03-09
another Phase III NALA study showed that for 621 patients who had received ≥2-line HER-2-positive metastasis breast cancer, the Nelatini-Carpentamine treatment group showed a 24 percent lower risk of disease progress or death (HR-0.76, P-0.006), and PFS showed a significant improvement in OS.
-
Junshi Bioanti-TIGIT Monoanti-JS006 Injection was approved for clinical trials
Time of Update: 2021-03-09
On January 27, Junshi Bio announced that the anti-TIGIT monoantigen JS006 injection was approved for clinical trials of the drug.
preclinical trials have shown that anti-TIGIT antibodies and anti-PD-1/PD-L1 antibodies can act in synergetic anti-tumor effects.
-
The "love" between man and pharmacy spanning thousands of years
Time of Update: 2021-03-09
Love: Modern- Pharmaceuticals entered a new era In the 10th century, drug development experienced three leaps and 10 years later, the industrial era also brought about a leap forward in technology in various fields, clinical began to enter the era of biopharmaceuticals.
-
National collection series (one) the fourth batch of collection open the bid! The starting and bottom player competition pattern
Time of Update: 2021-03-09
Fourth batch of volume procurement part of the variety details data source: Shanghai Sunshine Pharmaceutical Procurement Network, Zhongkang CMH, Zhongkang Kais system, Zhongkang Industrial Capital Research Center finishing Note: hospital-side sales data source public second- and third-tier hospital market main varieties analysis chart 2.
-
An analysis of the general situation and development trend of the cell therapy drug industry
Time of Update: 2021-03-09
1 China's registered stem cell drug clinical trial details data source: CDE, Firestone creation finishing (ii) global market cell therapy products market is one of the fastest growing sub-sectors of the biopharmaceutical market.
-
Sangershi Risk Express Series: China's chemotherapy drug market risk briefing
Time of Update: 2021-03-09
Chemotherapy drugs can act on the growth and reproduction of tumor cells in different links, inhibit or kill tumor cells, is currently one of the main means of treating tumors. according to the sourc
-
Orphan Medicine Weekly | Innovative immune-activated cells, 8 therapies, such as recombination proteins...
Time of Update: 2021-03-09
Drugs: Romiplostim Research and Development Enterprise: Amgen Treatment of Diseases: Thrombocytopenia Caused by Chemotherapy Introduction: Rombocytopenia Introduction: Rombocytopenia is a recombinant protein that belongs to plateocyte-producing (TPO) subjectors that stimulate in-cell transcription by binding to TPO subjects, resulting in an increase in plateplate production.
-
Fosun Pharma's new crown vaccine has been urgently used in Hong Kong
Time of Update: 2021-03-09
(Pharmaceutical Mingkangde) Tiantian Bio and MorphoSys announced that TJ2101 clinical studies completed the first patient dosing January 26, Tiantian Biology and German MorphoSys jointly announced that TJ210/MOR210 single-drug treatment recurrence or resusable advanced solid tumors of the United States Phase 1 dose climbing trial has completed the first patient.
-
Bai osaitu has a strategic cooperation agreement with Libero Thera of Japan
Time of Update: 2021-03-09
Libero Thera is responsible for antigen preparation and participation in in vitro antibody screening, and Baiosaitu will use its RenMab® mouse platform to conduct GPCR antibody discovery and complete the screening of lead antibody candidate molecules through drug ability evaluation techniques in animals.
-
It's sunny! Take 5 more than $1 billion imitation 32 over-reviewed varieties bright...
Time of Update: 2021-03-09
Recently, Zhengda Qing pharmaceutical industry happy news: Androtini's fourth adaptive disease was approved, 5 varieties to choose the fourth batch of collection. meters of intranet data show that i
-
Keystone Pharmaceuticals anti-PD-L1 monoantigen is intended to be included in the breakthrough treatment varieties
Time of Update: 2021-03-09
Source: Pharmaceutical Mission China National Drug Administration Drug Review Center (CDE) the latest publicity, Keystone Pharmaceuticals Class 1 bio-new drug recombinant anti-PD-L1 human monoclonal antibody injection is intended to be included in the breakthrough treatment varieties, the proposed adaptation is: recurrence or refractory extraterrestrial natural killer cells / T cell lymphoma (R/R ENKTL).
-
Gifeitinib is "named" as a small molecule targeting drugs
Time of Update: 2021-03-09
Figure 2 Pharmaceutical segment composition in the field of anti-tumor drugs according to the PDB drug comprehensive database statistics (see Figure 3), in the small molecular targeting drug family, we found that imatinib, giffeitinib and ecstasy in 2016, cumulative sales reached 1,155 million yuan, accounting for 61.8% of the entire family at that time!
-
The eight new drugs were approved in China from AstraZeneta, Hesco and other companies
Time of Update: 2021-03-09
According to the CDE Priority Review Public Information, The new adaptive disorder approved by Dagrid Net this time is - for adult patients with reduced blood test scores for heart failure (HFrEF), reducing the risk of cardiovascular death and worsening heart failure, and improving heart failure symptoms.
